Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Payables (2016 - 2025)

RedHill Biopharma has reported Payables over the past 15 years, most recently at $731000.0 for Q4 2025.

  • Quarterly Payables fell 37.41% to $731000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $731000.0 through Dec 2025, down 37.41% year-over-year, with the annual reading at $731000.0 for FY2025, 37.41% down from the prior year.
  • Payables was $731000.0 for Q4 2025 at RedHill Biopharma, down from $835000.0 in the prior quarter.
  • Over five years, Payables peaked at $119.4 million in Q4 2022 and troughed at $731000.0 in Q4 2025.
  • The 5-year median for Payables is $4.4 million (2022), against an average of $13.1 million.
  • Year-over-year, Payables soared 924.06% in 2022 and then plummeted 97.26% in 2023.
  • A 5-year view of Payables shows it stood at $11.7 million in 2021, then soared by 924.06% to $119.4 million in 2022, then plummeted by 97.26% to $3.3 million in 2023, then crashed by 64.37% to $1.2 million in 2024, then plummeted by 37.41% to $731000.0 in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Payables are $731000.0 (Q4 2025), $835000.0 (Q2 2025), and $1.2 million (Q4 2024).